The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Hanmi loses Boehringer, gains Roche in $800M-plus cancer-partner shuffle.....           Eli Lilly's Portrazza turned away in final NICE guidance.....           Failed Eylea combo trial throws a wrench in Regeneron's expansion effort.....           Sanofi taps Bayer vet to lead soon-to-be-bolstered consumer unit.....           Horizon to fork over $65M to settle Express Scripts rebate clash.....           Amgen, Arrowhead to develop gene therapies for cardiovascular disease.....           Bayer, DelSiTech partner to develop new drug delivery technology for ophthalmology.....           Hanmi Pharmaceutical signs license deal with Genentech for novel Oral RAF inhibitor.....           Novo Nordisk plans to cut 1,000 jobs amid increasing competition.....           Catabasis, Sarepta partner to explore combination drug for Duchenne muscular dystrophy.....           J&J's next-gen psoriasis med tops Humira in head-to-head showdown.....           Intra-Cellular Therapies? schizophrenia drug fails in phase 3 trial.....           UPDATED: U.S. payer pressures force Novo Nordisk to cut loose 1,000 staffers.....           UPDATED: Mylan could face big Medicaid bill after underpaying EpiPen rebates, CMS says.....           Ex-Novartis consumer vet takes Glaxo JV reins from CEO-bound Walmsley.....           GSK unloads the last of its Aspen stake with $620M sale.....           Johnson & Johnson hid faulty device concerns during key Xarelto study: BMJ.....           Vertex scores new Orkambi market but chops sales guidance anyway.....           Novartis and Amgen?s erenumab succeeds in phase 3 study in migraine prevention.....           Pfizer closes Medivation acquisition.....           Boehringer, ViraTherapeutics partner to jointly develop oncolytic virus therapy platform.....           Oncodesign to buy GSK's French research center.....           Intra-Cellular Therapies? schizophrenia drug fails in phase 3 trial.....           U.S. payer pressures force Novo Nordisk to cut loose 1,000 staffers.....           Troubled psoriasis med brodalumab debuts in Japan with mighty Cosentyx in its sights.....           Chasing Sanofi's Dengvaxia, Sun Pharma licenses dengue fever vaccine from Indian biotech lab.....           Pfizer's Prevnar 13 sales set for decline as patient pool shrinks, report says.....           Doctors ready to roll with Sarepta's $300K DMD med Exondys 51. Are payers?.....           Do ADHD meds really help kids finish homework? Maybe not, study says.....           Did Mylan find a way to overcharge Medicaid for EpiPen? Senators ask DOJ to find out.....           Teva at court's 'mercy' in key Copaxone patent trial: Analysts.....           Bristol-Myers to test Opdivo with Nektar Therapeutics drug in five tumor types.....           C4X Discovery enters into multi-target, risk-sharing alliance with Evotec.....           ProNAi secures global rights to Chk1 inhibitor cancer drug candidate CCT245737.....           Redx Pharma discovers breakthrough antibiotic compounds.....           FDA grants rare pediatric disease designation to Summit Therapeutics? DMD drug.....           Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution.....           McCann Health looks to break the pharma consulting mold with new unit.....           Aralez finally scores FDA approval for Yosprala, but the combo med could be a hard sell.....           Indian union plots mass protest against 'unfair' treatment of pharma sales reps.....           Mylan CEO Bresch used a sky-high tax rate to lowball EpiPen profits by 66%.....           J&J's Stelara, squeezed in psoriasis, grabs new market with Crohn's approval.....           Amgen talks up Plan B as Kyprolis fails key first-line myeloma trial.....           Mylan, Lupin, others now in the mix for $1.1B Bayer derm buy.....           As hep C proves a 'flash in the pan' once again, Gilead's sales will 'erode massively': Analyst.....           Pfizer scraps plan to split into two companies.....           PAREXEL agrees to acquire ExecuPharm.....           Sanofi secures $43m US funding to spur Zika vaccine development.....           GW Pharmaceuticals unveils second positive phase 3 trial for Epidiolex in LGS treatment.....           FDA approves Janssen Biotech's STELARA for Crohn?s disease.....           Kite Pharma's lead cancer drug shows encouraging results.....           UPDATED: Pfizer's long-anticipated split-up isn't happening. So what's next?.....           Novartis hopes speedy new diagnostic gadget can help boost Xolair scripts.....           Sun Pharma founder Dilip Shanghvi heads this year's list of Asian pharma billionaires.....           FDA puts 'priority' stamp on Sanofi and Regeneron's next blockbuster hopeful.....           Merck's Keytruda to make its China debut as a resort-island draw for medical tourists.....           What's next for Valeant's Sprout biz? A huge impairment charge, analyst predicts.....           Should GSK investors be disgruntled about its insider CEO pick? If they want big changes, yes.....           Sanofi grabs $43M in U.S. government funds to advance Zika vaccine into Phase II.....           Novartis' Ilaris nets a trio of rare-disease nods in untapped markets.....           FDA approves expanded use of Novartis? Ilaris to treat three rare periodic fever syndromes.....           Janssen Biotech files US regulatory application for Sirukumab in rheumatoid arthritis.....           BioLineRx in-licenses novel treatment for liver failure conditions.....           ERYTECH completes patient enrollment in phase 2 trial of eryaspase for pancreatic cancer.....           Pharmaron enters into non-binding heads of terms with MSD over Hoddesdon UK site.....           The long-anticipated Pfizer split-up won't happen, CEO says.....           Monsanto brand name may get the circular file in proposed Bayer acquisition.....           Baseball great Griffey steps up to the plate for Bayer prostate cancer campaign.....           It's out with the old CEO, in with the new as Endo's Campanelli takes De Silva's seat.....           Indivior faces suit by 35 states claiming it 'illegally' blocked Suboxone competitors.....           Novartis' new Zykadia data put first-line nod in sight, but a Roche showdown looms.....           Amgen's Humira biosim, Amjevita, passes FDA milestone on long road to market.....           Teva's second phase III study of SD-809 in TD shows statistically significant results.....           Teva's second phase III study of SD-809 in TD shows statistically significant results.....           UK?s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq.....           UK?s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq.....           Sanaria's preventative vaccine for malaria gets FDA fast track designation.....           Sanaria's preventative vaccine for malaria gets FDA fast track designation.....           Evotec forms research collaboration with Inserm Transfert in oncology.....           Evotec forms research collaboration with Inserm Transfert in oncology.....           Ligand Pharmaceuticals licensing deals with Seelos Therapeutics for four programs.....           Ligand Pharmaceuticals licensing deals with Seelos Therapeutics for four programs.....           NICE backtracks on its 'no' for Strensiq, but Alexion still isn't satisfied.....           Lawmakers smack Mylan CEO Bresch for pay, plane and pricing at EpiPen hearing.....           Glenmark takes aim at Celgene's Abraxane with complex generic deal.....           The Allergan megadeal speculation--now featuring Gilead--just won't stop.....           UPDATED: UnitedHealth adds to formulary pain for Sanofi, Amgen and Novartis.....           Facebook?s Mark Zuckerberg announces $3bn funding to help cure diseases.....           Facebook?s Mark Zuckerberg announces $3bn funding to help cure diseases.....           Turing advances several experimental compounds into pre-clinical development.....           Turing advances several experimental compounds into pre-clinical development.....           AstraZeneca selects LLamasoft as supply chain design technology partner.....           AstraZeneca selects LLamasoft as supply chain design technology partner.....           Takeda, Affilogic partner to develop CNS therapies.....           Takeda, Affilogic partner to develop CNS therapies.....           FDA approves Janssen?s new type 2 diabetes combination therapy.....           FDA approves Janssen?s new type 2 diabetes combination therapy.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
PharmSci 2016 Conference - Chair's review

The Chair of the Academy of Phamaceutical Sciences, Dr Linda Hakes, gives a brief review of the 7th APS International PharmSci Conference, held in Glasgow on 5-7 September 2016.

"2016 has come to an end and although I admit that I am probably biased, I think it was a fantastic three days. The venue, the Technology and Innovation Centre at Strathclyde University, was well equipped to handle the conference and the facilities are modern and efficient.

All of the conference sessions (as far as I could tell) were well attended and the plenary lectures were all excellent, covering topics ranging across the spectrum of pharmaceutical sciences, embracing chemistry, pharmacology, medical devices, formulation, pharmacokinetics and spectroscopy.

A highlight of the social side was the Civic Reception in the City Chambers, a magnificent building on George Square, where we were warmly welcomed by the Bailey Steward on behalf of the Lord Provost of Glasgow.






As always the Black Tie Dinner was a great success and we were pleased to have Prof. Sandy Florence as guest speaker. Again, the venue was truly impressive – the Barony Hall.





To sum up, I believe we enjoyed a conference full of good science, excellent networking opportunities, and highly enjoyable social events. If you weren’t there, why not make a note for next year –
Tuesday 5 - Thursday 7 September 2017 at the University of
Hertfordshire .

See you there!"

Latest News
APS Symposium on the Digital Design of Drug Products
MONDAY, 13 JUNE 2016
APS Symposium on the Digital Design of Drug Products 1st July 2016, University of Leeds. The design of new medicinal products is a risky and lengthy process. Current approaches utilise a make and test philosophy to understand processing risk. This requires large amounts of materials and knowledge is often limited by short development timelines and availability of input materials. Hence formulations are often developed that merely accommodate variability in drug substance rather than making it an opportunity and thus a heavily over-engineered formulation and process can be produced. The area of digital design has the opportunity to revolutionise the development and manufacturing of new medicines by utilising both mechanistic and big data approaches to produce holistic models for our processes. This will allow optimal processes and materials to be produced which will permit more rapid development and result in improved robustness of manufacturing processes. This event brings together the concept of materials engineering with state of the art knowledge around modelling of materials and processes. It will provide information around initiatives in the pharmaceutical arena where data sharing is helping to produce better guidelines for processes. An opportunity will also be provided to learn about the recently £24M funded ADDoPT (Advanced Digital Design on Pharmaceutical Therapeutics) project which is aimed to provide new tools to the industry in the area of materials manufacture and processing. The meeting is organised by the Academy of Pharmaceutical Sciences but is kindly facilitated by BACG and CGOM. It is a must attend for scientists and leaders in the pharmaceutical development and manufacturing sector as well as an opportunity for other manufacturing industries to learn about new developments that could be adopted on their processes. For more details please contact Registration for the APS Symposium is now open. Register here: On Thursday evening, before the APS Symposium, Tommy Dolan will be giving an evening lecture on “The Future of Medicines Manufacture: Towards Digital Design”. The Conference dinner will also be taking place on Thursday evening. Expressions of interest for the evening lecture series will be opened closer to the event but the conference dinner and accommodation at the University of Leeds can be booked in addition to your APS registration. Friday 1st July – APS Symposium 09:30 10:00 Registration & Refreshments 10:00 10:05 Welcome – Richard Storey, AstraZeneca/APS Treasurer 10:05 10:45 Keynote #1 – Calvin Sun, University of Minnesota The Materials Science Tetrahedron – The Academic Vision Invited modelling presentations 10:45 11:15 Mojtaba Ghadiri, University of Leeds Particle breakage modelling 11:15 11:45 Jim Litster, University of Sheffield Wet granulation experimental and modelling 11:45 12:15 James Elliott, University of Cambridge Compaction modelling (and DEM solution on DEM modelling) 12:15 13:20 Lunch 13:20 13:50 Industrial Perspective – Kendall Pitt, GlaxoSmithKline The MCS – The Drive From Industry 13:50 14:30 Keynote #2 – Amrit Paudel, Research Centre for Pharmaceutical Engineering Stability by Design 14:30 14:50 Refreshment Break 14:50 15:20 Richard Storey, AstraZeneca Towards the Perfect Particle: What are the important design attributes? 15:20 16:00 Costas Pantelides, Process Systems Enterprise ADDoPT Vision: System-based Pharmaceutics 16:00 16:30 Summary and Close
APS and RPS Awards Announcement
APS Innovative Science Award Lecture 2016. The Academy of Pharmaceutical Sciences present the Innovative Science Award and invite pharmaceutical scientists to submit an application. Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry. Prize The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the Innovative Science Award Lecture on their work at APS PharmSci 2016. Submission Criteria Applicants are requested to submit their CV and a synopsis of their research of not more than 500 words, focussing on its importance to the pharmaceutical industry. Entries should be submitted via email to Alan Ramsay at including ‘Innovative Science Award 2016’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. Entries will be judged by an APS panel. Closing Date for Entries 31st May 2016. . 2016 Royal Pharmaceutical Society Science Award Applications are invited for the 2016 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the 7th Academy of Pharmaceutical Sciences International PharmSci Conference on the 7th September 2016. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2016, applicants must have a proven record of independent research and published work that shows outstanding promise. Applicants are invited to submit the following details by 20th May 2016:. Full CV detailing personal information, past and present appointments, research responsibilities and published work. List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations. Details of research grants awarded and the candidate’s role. Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards. A brief resume of two pages should also be submitted with the CV, indicating discoveries made. Please note copies of publications are not required. Applications should be made by 20th May 2016 preferably by email ( or by post to: Jayne Lawrence, Chief Science Advisor Royal Pharmaceutical Society 66 East Smithfield, London, E1W 1AW.
APS Manufacturing Classification System
TUESDAY, 10 MAY 2016
Be Part of a Successful Global Partnership –APS Manufacturing Classification System . 'Pharmaceutical Sciences: Improving World Health'. Monday 5th – Wednesday 7th September 2016 at the Technology and Innovation Centre, University of Strathclyde, Glasgow. A roundtable session has been organised on Tuesday 6th September at 12.15-13.30, co-chaired by Kendal Pitt (GSK) and Gavin Reynolds (AstraZeneca) giving you the opportunity to input into the Manufacturing Classification System (MCS) and its implementation.. The MCS is a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the Active Pharmaceutical Ingredient (API) and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing based on "ideal" ranges for API physical properties and therefore indicate how robust a manufacturing process is likely to be in relation to those properties.. This represents a very successful APS-driven Industry collaboration which has already resulted in a publication entitled “‘A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms”. This was the most downloaded article in Pharmaceutical Development & Technology of 2015 and the cross-industry authors have been commended for their contribution to Pharmaceutical Development & Technology.. For more information and to register for the conference, go to on or before 31st July 2016 to take advantage of the Early Bird Rates for the conference..
APS Alternatives to Antibiotics Meeting
APS Alternatives to Antibiotics Meeting Thursday 16th June 2016 Burleigh Court - Loughborough. Keynote speaker- Dr Lloyd Czeplewski, Chairman of the Wellcome Trust/Department of Health funded review on Alternative to Antibiotics. This one day meeting focussing on exploration of possible opportunities for alternative approaches to traditional antibacterial compounds as potential clinical approaches for treating infectious diseases will be held on Thursday 16th June 2016 at Burleigh Court, Loughborough, Leicestershire ( organised by the APS Microbiology and Anti-infectives Focus Group.. Background to the Meeting:. The withdrawal last Century by the majority of Big Pharma from antibiotic research and development programmes, coupled with other aspects such as a lack of global stewardship over use, has led to the current situation where resistance has left a critical lack of efficacious compounds. The pipeline for development of new antimicrobial agents is critically stagnant and the time to seriously examine viable alternatives for tackling multi-drug resistant pathogens has arrived. The purpose for this meeting will be to allow delegates to hear presentations on a series of alternative approaches including bacteriophage and endolysin therapy, probiotics, antibody technology and immune intervention, which collectively represent the most likely of the alternative approaches to yield genuine clinical impact. Our speakers will highlight the current knowledge base of development in the field in pursuit of discovery of alternatives to antibiotics.. The purpose and aims of the APSGB Microbiology and Anti-Infectives Focus Group is to provide a forum for the discussion of all aspects of microbiology and anti-infectives research and development in the pharmaceutical industry and academia, to underpin the importance of microbiology to the pharmaceutical sciences and innovation, and to provide continuing education, resources and a voice for pharmaceutical scientists in the challenging area of antimicrobials development.. Meeting Format: . We are very pleased to offer a stimulating one day programme of presentations from high profile speakers who are leading experts in their particular fields of research into alternative approaches to traditional small molecule antibiotics, and include representatives of academia, biotechnology SMEs and the pharmaceutical industry.. The Keynote lecture will be delivered by Dr Lloyd Czeplewski, Chairman of the Wellcome Trust/Department of Health funded review on Alternative to Antibiotics, which was published in Lancet Infectious Diseases in January 2016 ( Dr Czeplewski is Founder and Director of Chemical Biology Ventures in and Abgentis, is an international opinion leader and successful scientist entrepreneur in the antibacterial R&D sector. He is currently a champion of the Alternatives to Antibiotics pioneering approaches for treatment of infectious diseases and he will be speaking specifically on this topic.. For more information and registrations, please visit us online at:.
Follow us
Upcoming Events
APS Biopharmaceutics Basic Workshop
12 October 2016
APS Board, Advisory Board & ELT Meeting
19 - 20 October 2016
APS PharmaFocus Day
November 2016
MIBio 2016: Stability of biopharmaceuticals
9 November 2016
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.